Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadunolimab (CAN04) plus FOLFIRINOX in metastatic pancreatic cancer
NCT04990037Phase 1Completed
- Sponsor
- Cantargia AB
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of nadunolimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Cantargia AB. Primary endpoints: Treatment-Emergent Adverse Events up to 6 months, Dose-Limiting Toxicities at Day 28 and 3 more. Started Jul 2021; status: completed.
02
Drugs
nadunolimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04990037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990037.